Alterations in EGFR—such as overexpression, exon 19 deletions, and the L858R substitution in exon 21—are key oncogenic drivers in non-small cell lung cancer (NSCLC) [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.